Abstract
Budd–Chiari syndrome and membranous obstruction of the inferior vena cava frequently result in the development of mostly benign hepatic lesions. In cases of membranous obstruction of the inferior vena cava, which is prevalent mostly in the East, these lesions often progress to hepatocellular carcinoma. In contrast, malignant transformation has not yet been recognised in patients with isolated hepatic vein thrombosis. We report the case of a 37-year-old male Caucasian who presented with acute Budd–Chiari syndrome without involvement of the inferior vena cava. Despite porto-caval shunting, a hepatocellular carcinoma developed within several months. Three hepatic lesions were treated by radiofrequency thermal ablation until liver transplantation was performed. This report emphasises the possibility of malignant transformation of regenerative nodules in patients with disturbed hepatic perfusion in general. Physicians must be aware of this when assessing regenerative nodules, especially as no unambiguous predictors for the development of hepatocellular carcinoma have been identified so far.
Background
The common definition of Budd–Chiari syndrome (BCS) includes both isolated thrombosis of the hepatic veins (classic BCS) and the (membranous) obstruction of the inferior vena cava (MOVC),1,2 despite distinct aetiologic, epidemiologic and prognostic features.3–5 Only MOVC regularly gives rise to malignancy—that is, hepatocellular carcinoma (HCC). MOVC occurs predominantly in black South Africans and Japanese, rarely in western countries.6–8 In contrast, development of HCC in classic BCS is a singular event, except for cases with longstanding cirrhosis caused by thrombosis of the hepatic veins9 with an incidence of HCC similar to other types of chronic liver disease.10
We report the case of a 37-year-old male Caucasian with classic BCS followed by the rapid development of liver cirrhosis and HCC. The case will be discussed with particular reference to actual developments in the knowledge regarding the differences between classic BCS and MOVC and their potential to cause malignant transformation.
Case presentation
A 37-year-old male Caucasian presented in 2004 with increasing abdominal girth, mild epigastric pain and painless jaundice, which had developed within 1 week. After 2 weeks in another hospital he was transferred to our unit for evaluation for liver transplantation because of suspected alcoholic cirrhosis. Before the onset of the symptoms the patient felt well and healthy, and he was not taking any medication. His past medical history was unremarkable, in particular regarding previous icteric episodes or hepatic disorders; he denied smoking and past or current alcohol abuse. The family history revealed no thrombotic, hepatic or haematological disease or malignancy.
Besides jaundice, the physical examination revealed ascites. The liver edge was palpable 8 cm below the costal arch. The results of relevant routine laboratory studies are shown in table 1. Extended laboratory studies (including antiphospholipid antibodies, lupus anticoagulant, antinuclear antibodies (ANA), antimitochondrial antibodies (AMA), smooth muscle antibodies (SMA), liver membrane antibodies (LMA), hepatitis (A,B,C) serology, and FACS analyses for paroxysmal nocturnal haemoglobinuria) demonstrated only a protein C and S deficiency.
Table 1.
Relevant laboratory parameters at admission to our unit
| Parameter | Reference | Result |
| Creatinine | <88 μmol/l | 106 |
| Total bilirubin | <17 μmol/l | 43 |
| Direct bilirubin | <5 μmol/l | 14 |
| ASAT | <0.52 μmol/lxs | 4.47 |
| ALAT | <0.56 μmol/lxs | 1.72 |
| GGTP | <0.63 μmol/lxs | 4.23 |
| Alkaline phosphatase | 0.60–1.75 μmol/lxs | 6.1 |
| Albumin | 35–52 g/l | 31 |
| C reactive protein | <5.0 mg/l | 28 |
| α-Fetoprotein (AFP) | <6.2 ng/ml | 1.7 |
| INR | 0.90–1.25 | 2.32 |
| Activated Protein S | 73–130% | 33 |
| Protein C | 70–140% | 53 |
| APC ratio | >2.2 | 2.5 |
| Factor II | 60–120% | 66 |
| AT III | >80% | 57 |
| Haemoglobin | 7.3–9.9 mmol/l | 10.4 |
| Haematocrit | 0.37–0.47 l/l | 0.5 |
| Leucocytes | 3.80–9.80 Gpt/l | 13 |
| Thrombocytes | 140–440 Gpt/l | 410 |
Oesophago-gastroduodenoscopy revealed grade 3 oesophageal varices and gastro-oesophageal varices (Sarin type I). Ultrasound examination showed an enlarged liver (16 cm cranio-caudal, 17.3 cm sagittal diameter) with irregular surface, but homogenous parenchyma without focal lesions. Bile ducts were normal. The spleen measured 11.8×4 cm. Generalised moderate ascites was detected. In Duplex ultrasound, hepatic veins were not detectable, while the liver arteries appeared normal. Low intermittent hepatopetal flow (maximal 6 cm/s) was detected in the portal veins. The diagnosis of BCS without involvement of the inferior vena cava was confirmed by magnetic resonance imaging (fig 1).
Figure 1.
Initial magnetic resonance image (MRI) showing an enlarged liver without focal lesions, but inhomogeneous and delayed contrast medium uptake. No thrombosis or other flow obstruction of the vena cava is evident, the hepatic veins are not visible (as depicted, angio-MR). Splenic and portal veins are perfused with a delayed contrast medium uptake. Moderate ascites is present.
A transjugular intrahepatic portosystemic shunt (TIPS) could not be deployed because the angiography catheter could not be passed into the liver veins. A surgical portocaval side-to-side interposition shunt (8 mm polytetrafluoroethylene (PTFE) prosthesis) was applied successfully, as confirmed by Duplex sonography and MRI. Intraoperatively, liver and bone marrow biopsies were performed. Liver histology is presented in fig 2. Bone marrow histology ruled out a myelodysplastic syndrome or monoclonal proliferation of plasma cells.
Figure 2.
Haematoxylin and eosin stain of the initial liver biopsy: advanced pericentral necrosis with modest cholestasis and mild inflammatory infiltration; beginning of portal fibrosis; regenerative hyperplasia of hepatocytes in periportal areas.
After shunt surgery, the patient recovered quickly and his liver function improved. During follow-up, abdominal ultrasound examinations and laboratory tests were performed every 4 months. At 13 months after the initial diagnosis, ultrasound revealed four solid tumours of the liver. α-Fetoprotein (AFP) was not increased (2.3 ng/ml). MRI showed several circular lesions of the liver up to 28 mm in diameter. Three of these lesions appeared to be compatible with the diagnosis of HCC (fig 3A). One of the suspicious lesions was biopsied under ultrasound guidance. A well differentiated HCC (G1) was diagnosed at histology (fig 4). No expression of AFP was detected immunohistologically, and CK8/18 was focally positive.
Figure 3.
Thirteen months after surgical portocaval shunting, T1 weighted MRI showing multiple hyperintense nodules with homogenous enhancement following contrast medium (panel A). Three of these nodules were also hyperintense in T2 weighted echo planar imaging (EPI-MRI, panel B), thus supporting the diagnosis of hepatocellular carcinoma. Panel C (computed tomography) and panel D (MRI) display the result after successful radiofrequency thermal ablation.
Figure 4.
Ultrasound guided biopsy of one of three suspicious lesions: liver fibrosis stage 3–4 with formations of pseudolobuli; glandular structures as well as trabecular formations with several cell layers compatible with well differentiated hepatocellular carcinoma (G1).
Treatment
The patient was evaluated for liver transplantation and placed on the waiting list at Eurotransplant, Leiden. To bridge the time to transplantation, three lesions were treated by two sessions of ultrasound guided percutaneous radiofrequency ablation (RFA). MRI and computed tomography scans after RFA showed necrotic areas compatible with the treated lesions (fig 3B).
Respecting the patient’s demand for additional treatment and considering its potentially beneficial anti-angiogenetic effect, the patient was treated with thalidomide in doses increasing up to 200 mg daily.11,12 Treatment was well tolerated without any side effects.
Twenty-two months after the initial diagnosis of BCS and 7 months after diagnosing HCC, orthotopic liver transplantation was performed. During the operation, the portocaval shunt appeared open. Histology of the explanted liver showed complete cirrhosis and multiple macroregenerative nodes. Necrotic liver tissue was found at the RFA sites, but no further malignant lesion could be found in the explant. A further course was complicated by primary graft failure. Re-transplantation was performed 10 weeks after initial liver transplantation and the patient recovered well.
Outcome and follow-up
Three years after re-transplantation, no recurrence of the malignant tumour was detected on regular follow-up. Liver function and perfusion are normal, as is the AFP value (3.9 ng/ml). The patient is well and in a good general condition.
Discussion
Aetiology of BCS
In about 50% of cases of BCS primary myeloproliferative disorders are found; other frequent causes are antiphospholipid syndrome, protein C deficiency, factor V Leiden mutation, and hyper-homocysteinaemia.13 In MOVC, a pathogenic role of local infections, phlebothrombosis or endothelial microlesions through respiratory movements of the diaphragm is discussed.5,14 Interestingly, in a very recent publication by Eapen et al15 the incidence of MOVC is reported to decrease. At present, the most common type of hepatic outflow obstruction seems to be an obstruction of both the inferior vena cava and hepatic vein. These changes are most likely related to improvements in hygiene and sanitation.
In our patient, the low protein C and S in the presence of normal factor II levels are suggestive of a primary deficiency even considering the impaired hepatic protein synthesis in the acute setting.16 Due to the multiple mutations responsible for protein C and S deficiency,17 genotyping is not practical. Thus, a definitive classification of the aetiology in the presented case is not possible.
Liver biopsy is not effective in diagnosing BCS in every case, but can provide information on the possible underlying primary disease.18 The histological patterns of the parenchymal response to outflow obstruction vary from veno-portal cirrhosis to pericentral necrosis, depending on the affected vessels.18,19 The biopsy in our case, taken 8 weeks after the onset of symptoms, correlated with the clinically diagnosed subacute form of BCS with occlusion of the hepatic veins (fig 2).
In our case, it might be speculated that the thrombotic event could represent the result of malignant disease rather than its cause. In fact, HCC is complicated by thrombotic events in advanced, large tumours, which compress or invade vascular structures, typically the portal or hepatic veins. The most frequent paraneoplastic syndromes of HCC are hypercholesterolaemia (incidence in HCC patients 11.4%), hypoglycaemia (2.8%), hypercalcaemia (1.8%), thrombocytosis (2.7%), and erythrocytosis (2.5%).20–22 The presence of a paraneoplastic syndrome predicts a poor response to therapeutic efforts and poor survival.20 These syndromes characteristically are found in patients with high serum AFP concentrations, and large tumour volume (>10 cm diameter, >30% of the liver volume or bi-lobal tumour involvement and metastasis).20,21 In our patient, no suspicious lesions of the liver were seen on ultrasound or MRI, both initially and during 1 year follow-up. AFP was completely normal and there was no evidence for metastatic disease. The tumour responded well to RFA and, thereafter, in the explanted liver, no evidence of remaining malignant hepatocellular lesions was found histologically. Thus, the hypothesis of a pre-existing HCC as the reason for hepatic vein thrombosis seems very remote.
Treatment of BCS
The main treatment objective in BCS is to avoid the development of cirrhosis and its complications by decompression of the liver.23 Porto-systemic shunting is performed in >90% of patients with BCS, either by surgical shunting,24 percutaneous angioplasty25 or by TIPS.26,27 In the present case, however, surgical shunting did not prevent the progress of mild fibrosis to complete cirrhosis.
Liver transplantation is an alternative to surgical shunting or may be necessary after failure of liver decompression by surgical shunt or TIPS.28 The 10 year survival rate of transplanted patients is about 70% with a low risk of recurrence of thrombotic events, when adequate long term anticoagulation is initiated early on after transplantation.29,30
Hepatic lesions in BCS in MOVC
Hepatic lesions are diagnosed in 40% of patients with BCS. Histologically, they are characterised as large regenerative nodules or nodular hyperplasia-like focal lesions.18
These lesions result from focal hyper-regeneration and develop independently from the grade of fibrosis.31 Varying grades of focal regeneration result from inhomogeneous perfusion of the liver in BCS.32 Venous outflow obstruction leads to an early decrease of portal flow, resulting in nodular regenerative hyperplasia or, if the perfusion is obstructed by large thrombi, infarcts of liver tissue. In chronic courses of BCS, additional portal vein thrombosis may occur in >50% of cases.17 Since low portal venous perfusion is compensated by increased arterial flow, large regenerative nodules of a rather focal nodular hyperplasia (FNH)-like type are observed.19
In European countries these lesions are generally regarded as benign. They may lead to gross changes in the size and shape of the liver, but not to HCC. In the East and on the Indian subcontinent, obstruction of the inferior vena cava is observed with high frequency.5,33 It regularly results in changes of hepatic venous outflow similar to classic BCS. Therefore, this entity is often included in the term Budd–Chiari syndrome. Combined obstruction of the inferior vena cava and the hepatic veins leads to the subsequent development of HCC in up to 47% of cases,6,8,33 especially in patients with longstanding obstruction.34 In a study from Turkey on BCS as a complication of Behçet’s disease,35,36 three out of 56 patients with hepatic vein thrombosis developed HCC. All three of these patients had combined thrombosis of the inferior vena cava and the hepatic veins as typical for Behçet’s disease.37
In a very recent report on the development of HCC on the background of BCS, including inferior vena cava obstruction, Moucari et al had followed a cohort of 97 patients with mostly Caucasian (69%) or African Jamaican background (22%) for at least 12 months.10 An obstructed inferior vena cava was described in 13% of cases. Roughly 60% of these patients were Caucasian, although cavla obstruction is considered a rare disease in this ethnic group. While this study confirms a high risk to develop HCC in patients with obstruction of the inferior vena cava (nine out of 11 patients were diagnosed with HCC), it remains unknown whether caval obstruction was the cause or rather the consequence of HCC.
This different risk of HCC in isolated hepatic vein thrombosis as compared to combined hepatic and caval vein obstruction has not been fully understood. Obviously, obstruction of the inferior vena cava is a more severe disease. In patients with MOVC, thrombosis of the hepatic veins is a rule5 and might lead to more pronounced liver damage, finally resulting in cirrhosis and HCC. However, in their cohort of 97 patients, Moucari et al10 reported an African Jamaican who had developed HCC in a non-fibrotic liver within 2 years of being diagnosed with classic BCS, and a Caucasian with obstruction of the inferior vena cava without hepatic fibrosis, who had presented with HCC at the time of initial diagnosis. The absence of fibrosis in these patients underlines the implication of impaired hepatic blood flow in the development of HCC.
Another explanation stresses the epidemiological differences between the two entities: in countries with a high incidence of MOVC, other causes of malignant liver disease are frequent including viral hepatitis, aflatoxine exposition, poor sanitation, poor nutrition and bacterial infections. Therefore, a superimposed exposition to carcinogenic influences might be assumed.5,38 However, no association between hepatitis B infection and HCC was detected in patients with BCS by Okuda et al.7 In our case, exogenous factors for the development of HCC could not be identified.
In conclusion, the development of HCC on the background of isolated hepatic vein thrombosis is a rare event, which is mostly related to longstanding cirrhosis caused by unresolved hepatic outflow obstruction. In the present case of BCS, the rapid progression to cirrhosis and HCC despite successful portocaval shunting is noteworthy. To the best of our knowledge, only one similar case with an HCC developing on the background of an isolated hepatic vein thrombosis and no fibrosis at the time of diagnosis of BCS has been reported in the literature.10 While the causal relationship between BCS and HCC remained largely speculative in previous case reports, in our case and the case of Moucari et al,10 a close follow up documented the course from acute BCS to HCC within several months.
In Eastern countries, the development of HCC in patients with membranous obstruction of the inferior vena cava is widely recognised,39 while in guidelines developed by western groups, this complication is mentioned in a footnote at best.2,40 With increasing global mobility, diseases and complications formerly restricted to “remote” countries—such as the development of HCC in MOVC—have to be added onto our list of diagnostic considerations.
Malignant transformation of regenerative nodules may also occur against the background of BCS in general. Although this might be a unique one-of-a-kind case, it calls for careful assessment of any hepatic lesions detected in such patients. In addition, it might be speculated that changes in hepatic perfusion in BCS including de novo angiogenesis could be relevant for the pathogenesis of HCC35,41,42
Learning points
Careful assessment of any hepatic lesions detected in the course of BCS is required in all patients.
Development of HCC in patients with membranous obstruction of the inferior vena cava is widely recognised.
Malignant transformation of regenerative nodules may occur against the background of isolated thrombosis of hepatic veins (classic BCS)
Acknowledgments
We thank Prof. R. P. Spielmann and Prof. C. Behrmann, University Clinic and Polyclinic for Diagnostic Radiology, Martin-Luther-University Halle-Wittenberg, for the excellent assistance in interpreting the CT- and MRI-images and the generous provision of appropriate copies for this report.
Footnotes
Competing interests: none.
Patient consent: Patient/guardian consent was obtained for publication
REFERENCES
- 1.Valla DC. Hepatic vein thrombosis (Budd-Chiari syndrome). Semin Liver Dis 2002; 22: 5–14 [DOI] [PubMed] [Google Scholar]
- 2.Janssen HL, Garcia-Pagan JC, Elias E, et al. European Group for the Study of Vascular Disorders of the Liver. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38: 364–71 [DOI] [PubMed] [Google Scholar]
- 3.Takeuchi J, Takada A, Hasumura Y, et al. Budd-Chiari syndrome associated with obstruction of the inferior vena cava. A report of seven cases. Am J Med 1971; 51: 11–20 [DOI] [PubMed] [Google Scholar]
- 4.Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998; 28: 1191–8 [DOI] [PubMed] [Google Scholar]
- 5.Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liv Dis 2002; 22: 15–26 [DOI] [PubMed] [Google Scholar]
- 6.Simson IW. Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa. Gastroenterology 1982; 82:171–8 [PubMed] [Google Scholar]
- 7.Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995; 22: 1–9 [DOI] [PubMed] [Google Scholar]
- 8.Kew MC, McKnight A, Hodkinson J, et al. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in Southern African blacks. Hepatology 1989; 9: 121–5 [DOI] [PubMed] [Google Scholar]
- 9.Havlioglu N, Brunt EM, Bacon BR. Budd-Chiari syndrome and hepatocellular carcinoma: a case report and review of the literature. Am J Gastroenterol 2003; 98: 201–4 [DOI] [PubMed] [Google Scholar]
- 10.Moucari R, Rautou PE, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut 2008; 57: 828–35 [DOI] [PubMed] [Google Scholar]
- 11.Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103: 119–25 [DOI] [PubMed] [Google Scholar]
- 12.Spangenberg HC, Zuber-Jerger I, Thimme R, et al. Systemic treatment for hepatocellular carcinoma. Zentralbl Chir 2003; 128: 906–10 [DOI] [PubMed] [Google Scholar]
- 13.Deltenre P, Denninger MH, Hillaire S, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001; 48: 264–8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Shrestha SM, Okuda K, Uchida T, et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 1996; 11: 170–9 [DOI] [PubMed] [Google Scholar]
- 15.Eapen CE, Mammen T, Moses V, et al. Changing profile of Budd Chiari syndrome in India. Indian J Gastroenterol 2007; 26: 77–81 [PubMed] [Google Scholar]
- 16.Janssen HLA, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96: 2364–8 [PubMed] [Google Scholar]
- 17.Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol 2006; 12: 1165–74 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology 1998; 27: 488–96 [DOI] [PubMed] [Google Scholar]
- 19.Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari-syndrome: a study in 17 explanted livers. Hepatology 2003; 37: 510–19 [DOI] [PubMed] [Google Scholar]
- 20.Luo JC, Hwang SJ, Wu JC, et al. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology 2002; 49: 1315–9 [PubMed] [Google Scholar]
- 21.Huh UY, Kim JH, Kim BH, et al. The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma (Korean, abstract in English). Korean J Hepatol 2005; 11: 275–83 [PubMed] [Google Scholar]
- 22.Hwang SJ, Luo JC, Li CP, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 2472–7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Bachet JB, Condat B, Hagège H, et al. Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. J Hepatol 2007; 46: 60–8 [DOI] [PubMed] [Google Scholar]
- 24.Orloff MJ, Daily PO, Orloff SL, et al. A 27-year experience with surgical treatment of Budd-Chiari syndrome. Ann Surg 2000; 232: 340–52 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Fisher NC, McCafferty I, Dolapci M, et al. Managing Budd-Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut 1999; 44: 568–74 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Mancuso A, Fung K, Mela M, et al. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol 2003; 38: 751–4 [DOI] [PubMed] [Google Scholar]
- 27.Perello A, Garcia-Pagan JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002; 35: 132–9 [DOI] [PubMed] [Google Scholar]
- 28.Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006; 44: 1308–16 [DOI] [PubMed] [Google Scholar]
- 29.Srinivasan P, Rela M, Prachalias A, et al. Transplantation of Budd Chiari syndrome. Transplantation 2002; 73: 973–7 [DOI] [PubMed] [Google Scholar]
- 30.Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol 2006; 44: 520–8 [DOI] [PubMed] [Google Scholar]
- 31.Ibarrola C, Castellano VM, Colina F. Focal hyperplastic hepatocellular nodules in hepatic venous outflow obstruction: a clinicopathological study of four patients and 24 nodules. Histopathology 2004; 44: 172–9 [DOI] [PubMed] [Google Scholar]
- 32.Honda H, Tajima T, Kajiyama K, et al. Vascular changes in hepatocellular carcinoma: Correlation of radiologic and pathologic findings. Am J Roentgenol 1999; 173: 1213–7 [DOI] [PubMed] [Google Scholar]
- 33.Van de Merwe CF, Arts MS. Primary liver cancer in the Transvaar. Hepatogastroenterology 1981; 28: 223–35 [Google Scholar]
- 34.Valla DC. The diagnosis and management of budd-chiari syndrome: consensus and controversies. Hepatology 2003; 38: 793–803 [DOI] [PubMed] [Google Scholar]
- 35.Bayraktar Y, Egesel T, Saglam F, et al. Does hepatic outflow obstruction contribute to the pathogenesis of hepatocellular carcinoma? J Clin Gastroenterol 1998; 27: 67–71 [DOI] [PubMed] [Google Scholar]
- 36.Bayraktar Y, Balkanci F, Bayraktar M, et al. Budd-Chiari syndrome: a commen complication of Behcet’s disease. Am J Gastroenterol 1997; 92: 858–62 [PubMed] [Google Scholar]
- 37.Bismuth E, Hadenque A, Hammel P, et al. Hepatic vein thrombosis in Behcet’s disease. Hepatology 1990; 11: 969–74 [DOI] [PubMed] [Google Scholar]
- 38.Kew MC, Hodinson HJ. Membranous obstruction of the inferior vena cava and its causal relation to hepatocellular carcinoma. Liver International 2006; 26: 1–7 [DOI] [PubMed] [Google Scholar]
- 39.Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine 1994; 73: 21–36 [DOI] [PubMed] [Google Scholar]
- 40.Menon KVN, Shah V, Kamath PS. The Budd-Chiari Syndrome. N Engl J Med 2004; 350: S78–85 [DOI] [PubMed] [Google Scholar]
- 41.O’Byrne KJ, Dalgleish AG, Browning MJ, et al. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000; 36: 151–69 [DOI] [PubMed] [Google Scholar]
- 42.Brancatelli G, Federle MP, Golfieri R, et al. Large regenerative nodules in Budd-Chiari-syndrome and other vascular disorders of the liver. CT and MR imaging findings with clinicopathologic correlation. Am J Roentgenol 2002; 178: 877–83 [DOI] [PubMed] [Google Scholar]




